pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,562 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1055Endpoints798BioPharma Dive306BioSpace231Fierce Biotech218onclive165raps82globenewswire health
therapy area
allOncology6226Rare Disease1508Cardiology1126Hematology1062Immunology1046Vaccines939Pulmonology
  • NSF launches $47 million pilot to create joint university-industry Ph.D. programs for life scientists
    The National Science Foundation, with funding announced by the Trump administration, is testing a new Ph.D. training model that blends academic study with industry experience. The $47 million pilo…
    STAT · 26d agoPositive↗ source
  • Prolonged hospital stays leave children isolated, urging change
    An author visiting a pediatric ward describes a young, nonverbal child with severe developmental delays who has been waiting months for a life-saving liver transplant. The child lies in a stark, ma…
    STAT · 27d agoNegative↗ source
← prev
page 19 of 63
next →
73
fda recalls51
fda medwatch46
fda press28
923
Psychiatry & CNS745
Ophthalmology451
Pain418
Endocrinology & Metabolism395
Infectious Disease374
Most-wanted fugitive Ronald Fischer operated under alias in biotech industry for two decades
A Rhode Island man on the most-wanted list was recently uncovered as a hidden employee in the biotech sector, having worked under a false identity for about twenty years. The individual, identifie…
STAT · 27d agoNegative↗ source
  • Nokia reports senior executive Kristen Pressner purchases 66,324 shares at €7.84 each
    Nokia Oyj filed a market abuse regulation disclosure on July 29, 2026 indicating that senior executive Kristen Pressner bought shares of the company. The transaction involved 66,324 ordinary share…
    globenewswire health · 27d agoDealNeutral↗ source
  • Vesa Pylvänäinen sells 117 Vaisala shares at €57 each
    Vaisala Corporation reported a share disposal by one of its senior managers, Vesa Pylvänäinen. On July 24, 2026, Pylvänäinen sold 117 of the company’s A‑shares at a price of €57 per share, resulti…
    globenewswire health · 26d agoRegulatoryNeutral↗ source
  • Nokia senior manager Mikko Hautala buys 7,103 shares at €7.84 each
    Nokia reported an insider transaction filed under market abuse regulation article 19. The filing lists Mikko Hautala, identified as "Other senior management", as the reporting person. On July 29,…
    globenewswire health · 27d agoCRLNeutral↗ source
  • Fauci invokes Fifth Amendment, declines to answer Covid-19 origins questions at Senate hearing
    At a Senate hearing on Wednesday, former U.S. health chief Anthony Fauci invoked his Fifth Amendment right and refused to answer lawmakers' questions about the Covid-19 pandemic and its origins. F…
    STAT · 27d agoRegulatoryNeutral↗ source
  • Morning Rounds flags overlooked pedestrian and cyclist deaths, upcoming Fauci Senate hearing, and research visa limits
    The latest Morning Rounds newsletter draws attention to the often‑ignored problem of deaths among pedestrians and cyclists, urging greater public health focus. It also notes that Dr. Anthony Fauci…
    STAT · 27d agoNeutral↗ source
  • Vaisala senior executive Vesa Pylvänäinen sells 117 shares at €57 each on Nasdaq Helsinki
    Vaisala Oyj announced that senior executive Vesa Pylvänäinen has disposed of company shares. The transaction was executed on July 24, 2026 and involved 117 ordinary shares at an average price of €…
    globenewswire health · 26d agoNeutral↗ source
  • Nokia senior manager Kristen Pressner purchases 66,324 shares at €7.84 each
    On July 29, 2026, Nokia Corporation disclosed that senior manager Kristen Pressner acquired shares of the company. The transaction involved 66,324 Nokia shares purchased at an average price of €7.…
    globenewswire health · 27d agoNeutral↗ source
  • Nokia senior manager Mikko Hautala buys 7,103 shares at €7.84 each
    Nokia Corporation disclosed that senior manager Mikko Hautala purchased 7,103 shares of the company on July 29, 2026. The transaction was reported under Article 19 of the EU Market Abuse Regulation…
    globenewswire health · 27d agoRegulatoryNeutral↗ source
  • FDA finds Capricor's Duchenne stem cell therapy failed to meet Phase 3 goals, contradicting company claims
    The U.S. Food and Drug Administration announced that the stem cell treatment from Capricor Therapeutics did not achieve the primary objectives in its Phase 3 trial for Duchenne muscular dystrophy.…
    STAT · 28d agoRegulatoryNegative↗ source
  • Claris Bio raises $118M Series B and appoints new CEO to advance eye-drug for limbal stem cell deficiency
    Claris Bio, a New Jersey biotechnology company, announced a $118 million Series B financing round co-led by Samsara BioCapital and Catalio Capital Management, with participation from Sofinnova Inve…
    BioPharma Dive · 28d agoDealPositive↗ source
  • GSK announces $2.5 billion annual cost-cutting plan to offset upcoming patent cliff
    GSK disclosed in its latest quarterly earnings that it will launch a three-year restructuring aimed at saving about £1.9 billion ($2.5 billion) each year. The plan is intended to cushion the impac…
    BioPharma Dive · 27d agoLayoffsNeutral↗ source
  • GSK CEO outlines £1.9bn cost-saving drive and aims to launch 20 Phase 3 trials by year-end
    GSK chief executive Luke Miels presented a three‑year plan to make the company more agile and generate significant cost efficiencies. The strategy targets £1.9 billion in annual savings by 2029, wi…
    STAT · 28d agoPositive↗ source
  • FDA staff raise concerns over Replimune's skin cancer drug data
    FDA staff have reiterated concerns that Replimune's investigational skin cancer therapy lacks sufficient data for approval. The agency highlighted the single-arm trial, in which patients previousl…
    STAT · 28d agoRegulatoryNegative↗ source
  • FDA’s AI push faces uncertainty after key leaders depart
    The FDA has been pushing artificial intelligence across the agency, unveiling a large-language-model tool called Elsa to help draft and summarize review reports and announcing plans to use agentic…
    BioPharma Dive · 28d agoRegulatoryNeutral↗ source
  • ProMIS Neurosciences early trial shows low brain bleeding and no swelling, hinting at safer Alzheimer’s drug
    ProMIS Neurosciences reported interim safety data from a early‑stage trial of its amyloid‑targeting therapy for Alzheimer’s disease. The analysis pooled data from participants receiving the investi…
    STAT · 28d agoPositive readoutPositive↗ source
  • Dementia finally shows a viable business model, AAIC2026 highlights economic shift
    At the Alzheimer’s Association International Conference in London this year, the author observed that dementia now appears to have a clear business model, a shift from earlier meetings where commer…
    STAT · 28d agoPositive↗ source
  • Biotech firms rush to develop gene-editing cure for rare alpha-1 antitrypsin deficiency
    A wave of biotech companies is intensifying efforts to cure alpha-1 antitrypsin deficiency (AATD), a rare liver and lung disorder, using gene-editing approaches. Companies such as Beam, Wave Life…
    STAT · 28d agoNeutral↗ source
  • Trump administration proposes four-year visa cap for foreign PhD students and postdocs, sparking science community concerns
    The Department of Homeland Security announced a new rule that limits the stay of international graduate students and postdoctoral researchers in the United States to four years on nonimmigrant visa…
    STAT · 27d agoRegulatoryNegative↗ source
  • Industry urges FDA to clarify and broaden QSP guidance for first-in-human dose selection
    Industry stakeholders have asked the U.S. Food and Drug Administration for more detailed guidance on using quantitative systems pharmacology (QSP) to select first-in-human doses in phase-1 studies.…
    raps · 28d agoRegulatoryNeutral↗ source
  • FDA draft guidance seeks clearer, more flexible QSP dose selection for first-in-human trials
    Industry groups have asked the FDA for more clarity in a draft guidance that outlines how sponsors can use quantitative systems pharmacology (QSP) to select doses for first-in-human studies. The r…
    raps · 28d agoRegulatoryNeutral↗ source
  • New name for PCOS aims to boost awareness and diagnosis for Black and Latina women
    Bontle Moka-Moliki, a 32-year-old from Atlanta, was diagnosed with endometriosis in 2019, fibroids a year later, and in 2024 received a diagnosis of a condition now called polyendocrine metabolic o…
    STAT · 28d agoPositive↗ source
  • CMS marks one year of Health Tech Ecosystem, unveils eight new pledge categories
    CMS held an event in Washington to review its Health Tech Ecosystem after a year. Officials highlighted progress toward data interoperability without new federal regulations. A coffin labeled "RI…
    STAT · 28d agoRegulatoryPositive↗ source